Hematología y Hemoterapia

Resultados: 392
Tipo Título / Nombre Autor(es) Año
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, et al 2018
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, et al 2017
Síndrome coronario agudo en pacientes con trombocitopenia. Respuesta Bermejo N 2017
Long Term Antiaggregation in a Patient with Severe Factor XI Deficiency Sigüenza R, Bermejo N, Casas I, Pérez Leal F, Cáceres S, Ibáñez F, et al 2017
Biological characterization of ITP patients that are non-responders to traditional therapies Rodríguez Otero P, Mateos MV, Joaquín ML, Miguel Teodoro H, Enrique MO, Rosiñol L, et al 2017
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2017
Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)— Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2017
Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, et al 2017
Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy Primo D, Hernández P, Serna J de la, Ribera JM, Vives S, Bergua J, et al 2017
Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) Ribera JM, Morgades M, Montesinos P, Martínez-Carballeira D, Gil C, Barba P, et al 2017